ContraFect Corporation (NASDAQ:CFRX) said it continues to advance lead programs toward new clinical studies and expects to file with regulatory authorities…
ContraFect (NASDAQ:CFRX) reported quarterly losses of $(0.46) per share. This is a 228.57 percent decrease over losses of $(0.14) per share from the same period last year.